Log in

Servier and Transgene combine in immuno-oncology

The pharmaceutical group Servier and the Alsatian biotech Transgene announced on Thursday a research agreement on the application of technologies called "viral vectorization" to developing cell therapies in the field of immuno-oncology.

Viral vectors are modified viruses for injecting a functional or therapeutically active gene into cells.

Transgene will be able to collect more than 30 million euros under this contract with Servier, whose initial term is three years, according to a press release.

In return, Servier will be able to tap into the collection of viral vectors of Transgene those which seem to him most appropriate to improve the production and the efficacy of allogeneic CART-T cell therapies, intended to treat cancers.

Servier has embarked on the development of allogeneic cell therapies since the end of 2015, by acquiring the rights of UCART-19 immunotherapy from another French biotech, Cellectis.

Servier has already entered into another agreement with US giant Pfizer to co-finance the clinical development of UCART-19 and to share the world markets. If authorized, Servier will have all marketing rights outside of the United States, which is a contract with Pfizer.

Servier seeks to become a leading actor in oncology in the long term, and has been pursuing a very active partnership strategy with biotechnology companies and other major laboratories since 2014.

a3p-100pxhaut logo


Commit to share
Transmit and progress together
Promoting innovation

The A3P Association is a major player in the pharmaceutical and biotechnology industry.
Created in 1986, it contributes to the good development of the production of medicines and clean and sterile equipment, it runs a network of professionals 21 000, manufacturers and suppliers, as part of International Congress and technical days.

It now has over 1700 members who share their technical experience, scientific and regulatory.

More info on video (Versiongb - drapeauitalie )

  group    administrators A3P
& Project Managers

letter   newsletter A3P